Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

Molecular Chaperones in the Cytosol: from Nascent Chain to Folded Protein

Hartl, F. U., & Hayer-Hartl, M. K. (2002) · Science · doi:10.1126/science.1068408 · Cited by 3,335

HDAC6 is a microtubule-associated deacetylase

Hubbert, C., Guardiola, A., Shao, R., Kawaguchi, Y., Ito, A., Nixon, A., Yoshida, M., Wang, X.-F., & Yao, T.-P. (2002) · Nature · doi:10.1038/417455a · Cited by 2,403

Histone deacetylases and cancer: causes and therapies

Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866

The Deacetylase HDAC6 Regulates Aggresome Formation and Cell Viability in Response to Misfolded Protein Stress

Kawaguchi, Y., Kovacs, J. J., McLaurin, A. C., Vance, J. M., Ito, A., & Yao, T. (2003) · Cell · doi:10.1016/s0092-8674(03)00939-5 · Cited by 1,529

Regulation of Signaling Protein Function and Trafficking by the hsp90/hsp70-Based Chaperone Machinery

Pratt, W. B., & Toft, D. O. (2003) · Experimental Biology and Medicine · doi:10.1177/153537020322800201 · Cited by 1,497

Crystal Structure of an Hsp90–Geldanamycin Complex: Targeting of a Protein Chaperone by an Antitumor Agent

Stebbins, C. E., Russo, A. A., Schneider, C. B., Rosen, N. X., Hartl, F. U., & Pavletich, N. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80203-2 · Cited by 1,370

Controlling the double helix

Felsenfeld, G., & Groudine, M. T. (2003) · Nature · doi:10.1038/nature01411 · Cited by 1,252

Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation

Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066

Role of the Heat Shock Response and Molecular Chaperones in Oncogenesis and Cell Death

Jolly, C. (2000) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/92.19.1564 · Cited by 1,052

Heat-shock protein 90, a chaperone for folding and regulation

Picard, D. (2002) · Cellular and Molecular Life Sciences · doi:10.1007/pl00012491 · Cited by 812

Suberoylanilide hydroxamic acid induces ROS-mediated cleavage of HSP90 in leukemia cells

Park, S., Park, J.-A., Kim, Y.-E., Song, S., Kwon, H., & Lee, Y. (2014) · Cell Stress and Chaperones · doi:10.1007/s12192-014-0533-4 · Cited by 21

NBM-T-BBX-OS01, Semisynthesized from Osthole, Induced G1 Growth Arrest through HDAC6 Inhibition in Lung Cancer Cells

Pai, J., Hsu, C., Hua, K., Yu, S.-Y., Huang, C.-Y., Chen, C.-N., Liao, C., & Weng, M. (2015) · Molecules · doi:10.3390/molecules20058000 · Cited by 21

Polycystic kidney disease and therapeutic approaches

Park, E.-Y., Woo, Y.-M., & Park, J.-H. (2011) · BMB Reports · doi:10.5483/bmbrep.2011.44.6.359 · Cited by 21

Heat Shock Protein 90 and Role of Its Chemical Inhibitors in Treatment of Hematologic Malignancies

Ho, N. A., Li, A. Y., Li, S., & Zhang, H. (2012) · Pharmaceuticals · doi:10.3390/ph5080779 · Cited by 21

Hybrid Enzalutamide Derivatives with Histone Deacetylase Inhibitor Activity Decrease Heat Shock Protein 90 and Androgen Receptor Levels and Inhibit Viability in Enzalutamide-Resistant C4-2 Prostate Cancer Cells

Rosati, R., Chen, B., Patki, M., McFall, T., Ou, S., Heath, E., Ratnam, M., & Qin, Z.-H. (2016) · Molecular Pharmacology · doi:10.1124/mol.116.103416 · Cited by 20

Ritonavir Interacts With Belinostat to Cause Endoplasmic Reticulum Stress and Histone Acetylation in Renal Cancer Cells

Isono, M., Sato, A., Okubo, K., Asano, T., & Asano, T. (2016) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.3727/096504016x14666990347635 · Cited by 21

Brain Aging: Hsp90 and Neurodegenerative Diseases

Wang, K., Shang, Y., & Dou, F. (2018) · Advances in experimental medicine and biology · doi:10.1007/978-981-13-1117-8_6 · Cited by 19

Epigenetic mechanisms underlying the therapeutic effects of HDAC inhibitors in chronic myeloid leukemia

Lernoux, M., Schnekenburger, M., Dicato, M. A., & Diederich, M. F. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.113698 · Cited by 22

The human immunodeficiency virus protease inhibitor ritonavir is potentially active against urological malignancies

Sato, A. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s79776 · Cited by 21

Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects

Sato, A. (2012) · OncoTargets and Therapy · doi:10.2147/ott.s23874 · Cited by 21

Givinostat, a type II histone deacetylase inhibitor, induces potent caspase-dependent apoptosis in human lymphoblastic leukemia

Li, Y., Zhao, K., Yao, C., Kahwash, S. B., Tang, Y., Zhang, G., Patterson, K., Wang, Q., & Zhao, W. (2016) · Genes & Cancer · doi:10.18632/genesandcancer.117 · Cited by 21

The dual functions of α-tubulin acetylation in cellular apoptosis and autophage induced by tanespimycin in lung cancer cells

Wang, Q., & Liu, X. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01453-y · Cited by 21

Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets

Santaniello, G., Nebbioso, A., Altucci, L., & Conte, M. (2022) · Marine Drugs · doi:10.3390/md21010024 · Cited by 20

Novel treatment strategies for chronic myeloid leukemia

Cruz‐Rodriguez, N., & Deininger, M. W. (2024) · Blood · doi:10.1182/blood.2024026312 · Cited by 22

CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer

Ignacio, R. M. C., Dong, Y.-L., Kabir, S. M., Choi, H., Lee, E.-S., Wilson, A. J., Beeghly-Fadiel, A. C., Whalen, M. M., & Son, D. (2018) · Oncotarget · doi:10.18632/oncotarget.24231 · Cited by 21

Targeting hsp90 family members: A strategy to improve cancer cell death

Calderón, P. B., Beck, R., & Glorieux, C. (2019) · Biochemical Pharmacology · doi:10.1016/j.bcp.2019.04.010 · Cited by 20

Homoharringtonine and SAHA synergistically enhance apoptosis in human acute myeloid leukemia cells through upregulation of TRAIL and death receptors

Cao, H., Cheng, Y., You, L., Qian, J., & Qian, W. (2013) · Molecular Medicine Reports · doi:10.3892/mmr.2013.1440 · Cited by 20

Small Molecule Modulators In Epigenetics

Swaminathan, V., Reddy, B. A., Selvi, R. B., Sukanya, M. S., & Kundu, T. K. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5466-1_18 · Cited by 21

Sirtuins regulate proteomic responses near thermal tolerance limits in the blue mussels Mytilus galloprovincialis and Mytilus trossulus

Vasquez, M. C., Beam, M., Blackwell, S. M., Zuzow, M. J., & Tomanek, L. (2017) · Journal of Experimental Biology · doi:10.1242/jeb.160325 · Cited by 22

Restoration of mutant hERG stability by inhibition of HDAC6

Li, P., Kurata, Y., Mahati, E., Ninomiya, H., Higaki, K., Taufiq, F., Morikawa, K., Shirayoshi, Y., Horie, M., & Hisatome, I. (2018) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2018.01.009 · Cited by 19

Molecular basis of the anti-cancer effects of histone deacetylase inhibitors

Epping, M. T., & Bernards, R. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.07.020 · Cited by 19

Targeting Histone Deacetylases for the Treatment of Immune, Endocrine & Metabolic Disorders

Lawless, M. W., Norris, S., O'Byrne, K. J., & Gray, S. G. (2009) · Endocrine Metabolic & Immune Disorders - Drug Targets · doi:10.2174/187153009787582441 · Cited by 19

Deactylase inhibition in myeloproliferative neoplasms

Mithraprabhu, S., Grigoriadis, G., Khong, T. T., & Spencer, A. G. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9590-4 · Cited by 19

Inhibition of histone deacetylase for the treatment of biliary tract cancer: A new effective pharmacological approach

Blüthner, T. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i35.4761 · Cited by 19

Honokiol from Magnolia spp. induces G1 arrest via disruption of EGFR stability through repressing HDAC6 deacetylated Hsp90 function in lung cancer cells

Liou, S.-F., Hua, K., Hsu, C., & Weng, M. (2015) · Journal of Functional Foods · doi:10.1016/j.jff.2015.03.018 · Cited by 19

Genetic deletion of the H istone D eacetylase 6 exacerbates selected behavioral deficits in the R6/1 mouse model for Huntington's disease

Ragot, A., Pietropaolo, S., Vincent, J. D., Delage, P., Zhang, H., Allinquant, B., Leinekugel, X., Fischer, A., & Cho, Y. H. (2015) · Brain and Behavior · doi:10.1002/brb3.361 · Cited by 21

Simvastatin-romidepsin combination kills bladder cancer cells synergistically

Okubo, K., Miyai, K., Kato, K., Asano, T., & Sato, A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101154 · Cited by 19

Modulation of cell sensitivity to antitumor agents by targeting survival pathways

Perego, P., Cossa, G., Zuco, V., & Zunino, F. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.07.030 · Cited by 18

The DAC system and associations with multiple myeloma

Ocio, E. M., & Miguel, J. F. S. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9589-x · Cited by 18

Enhanced radiosensitivity of EC109 cells by inhibition of HDAC1 expression

Zhang, B., Wang, Y., & Pang, X. (2010) · Medical Oncology · doi:10.1007/s12032-010-9559-3 · Cited by 18

An innovative approach to the treatment of Gaucher disease and possibly other metabolic disorders of the brain

Brady, R. O., Yang, C., & Zhuang, Z. (2012) · Journal of Inherited Metabolic Disease · doi:10.1007/s10545-012-9515-9 · Cited by 18

Opportunities and Challenges for Molecular Chaperone Modulation to Treat Protein-Conformational Brain Diseases

van der Putten, H., & Lotz, G. P. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0186-5 · Cited by 18

Bcr-Abl tyrosine kinase inhibitors: a patent review

Desogus, A., Schenone, S., Brullo, C., Tintori, C., & Musumeci, F. (2015) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.2015.1012155 · Cited by 19

The HDAC inhibitor SB939 overcomes resistance to BCR-ABL kinase Inhibitors conferred by the BIM deletion polymorphism in chronic myeloid leukemia

Rauzan, M., Chuah, C. T. H., Ko, T. K., & Ong, S. T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174107 · Cited by 18

Novel oral histone deacetylase inhibitor, MPT0E028, displays potent growth-inhibitory activity against human B-cell lymphomain vitroandin vivo

Huang, H.-L., Peng, C.-Y., Lai, M.-J., Chen, C., Lee, H., Wang, J.-C., Liou, J., Pan, S., & Teng, C. (2014) · Oncotarget · doi:10.18632/oncotarget.3213 · Cited by 18

Identification of a potent and stable antiproliferative agent by the prodrug formation of a thiolate histone deacetylase inhibitor

Suzuki, T., Hisakawa, S., Itoh, Y., Maruyama, S., Kurotaki, M., Nakagawa, H., & Miyata, N. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.117 · Cited by 18

The interplay between G protein-coupled receptor kinase 2 (GRK2) and histone deacetylase 6 (HDAC6) at the crossroads of epithelial cell motility

Lafarga, V., Mayor, F., & Penela, P. (2012) · Cell Adhesion & Migration · doi:10.4161/cam.21585 · Cited by 19

Epigenetic drugs for cancer treatment and prevention: mechanisms of action

Yu, X., & Guo, Z. S. (2010) · BioMolecular Concepts · doi:10.1515/bmc.2010.020 · Cited by 18

Inhibition of histone deacetylase 6 restores innate immune cells in the bone marrow in a lethal septic model

Zhao, T., Li, Y., Liu, B., Pan, B., Cheng, X. M., Georgoff, P. E., & Alam, H. B. (2015) · The Journal of Trauma: Injury, Infection, and Critical Care · doi:10.1097/ta.0000000000000897 · Cited by 18

A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways

Hwang, J. J., Kim, Y. S., Kim, M. J., Jang, S.-J., Lee, J., Choi, J., Ro, S., Hyun, Y., Lee, J. S., & Kim, C. (2009) · Anti-Cancer Drugs · doi:10.1097/cad.0b013e3283300a0f · Cited by 18

Error-protein metabolism and ageing

Hipkiss, A. R. (2008) · Biogerontology · doi:10.1007/s10522-008-9188-9 · Cited by 18

Synergistic action by multi-targeting compounds produces a potent compound combination for human NSCLC both in vitro and in vivo

Zhang, C., Zhai, S., Li, X., Zhang, Q., Wu, L., Liu, Y., Jiang, C., Zhou, H., Li, F., Zhang, S., et al. (2014) · Cell Death and Disease · doi:10.1038/cddis.2014.76 · Cited by 17

Fluorescent Ligand for Human Progesterone Receptor Imaging in Live Cells

Weinstain, R., Kanter, J. R., Friedman, B., Ellies, L. G., Baker, M. E., & Tsien, R. Y. (2013) · Bioconjugate Chemistry · doi:10.1021/bc3006418 · Cited by 17

4,5,6,7-Tetrahydro-isoxazolo-[4,5-c]-pyridines as a new class of cytotoxic Hsp90 inhibitors

Baruchello, R., Simoni, D., Marchetti, P., Rondanin, R., Mangiola, S., Costantini, C., Meli, M., Giannini, G., Vesci, L., Carollo, V., et al. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.01.056 · Cited by 17

Histone deacetylase inhibitor SAHA mediates mast cell death and epigenetic silencing of constitutively active D816V KIT in systemic mastocytosis

Lyberg, K., Abdulkadir, H., Grootens, J., Kjellander, M., Tirfing, M., Arock, M., Hägglund, H., Nilsson, G. P., & Ungerstedt, J. S. (2016) · Oncotarget · doi:10.18632/oncotarget.14181 · Cited by 17

New Concepts of Treatment for Patients with Myelofibrosis

Bose, P., Alfayez, M., & Verstovšek, S. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0604-y · Cited by 17

Recent Study of Dual HDAC/PARP Inhibitor for the Treatment of Tumor

Lu, H., Bai, L., Zhou, Y., Lu, Y., Jiang, Z., & Shi, J. (2019) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026619666190603092407 · Cited by 17

Dual-Targeted Therapy Circumvents Non-Genetic Drug Resistance to Targeted Therapy

Wang, W., Sun, Y., Liu, X., Kumar, S. K., Jin, F., & Dai, Y. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.859455 · Cited by 16

Stochasticity of anticancer mechanisms underlying clinical effectiveness of vorinostat

Omari, N. E., Khalid, A., Makeen, H. A., Alhazmi, H. A., Albratty, M., Mohan, S., Tan, C. S., Ming, L. C., Chook, J. B., & Bouyahya, A. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33052 · Cited by 16

Potential Prognostic Value of Histone Deacetylase 6 and Acetylated Heat-Shock Protein 90 in Early-Stage Breast Cancer

Park, Y., Lee, K. S., Park, S. Y., Kim, J. H., Kang, E. Y., Kim, S. W., Eom, K. Y., Js, K., & Kim, I. A. (2015) · Journal of Breast Cancer · doi:10.4048/jbc.2015.18.3.249 · Cited by 16

Therapeutic Efficacy of Lactonic Sophorolipids: Nanoceria-Assisted Combination Therapy of NSCLC using HDAC and Hsp90 Inhibitors

Naz, S., Banerjee, T., Totsingan, F., Woody, K., Gross, R. A., & Santra, S. (2021) · Nanotheranostics · doi:10.7150/ntno.57675 · Cited by 16

TAp73 Protein Stability Is Controlled by Histone Deacetylase 1 via Regulation of Hsp90 Chaperone Function

Zhang, J., Xu, E., & Chen, X. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.429522 · Cited by 18

To prevent neurodegeneration

Du, G., & Jiao, R. (2011) · Communicative & Integrative Biology · doi:10.4161/cib.4.2.14272 · Cited by 16

Design, synthesis and biological evaluation of β-peptoid-capped HDAC inhibitors with anti-neuroblastoma and anti-glioblastoma activity

Reßing, N., Marquardt, V., Gertzen, C. G. W., Schöler, A., Schramm, A. R., Kurz, T., Gohlke, H., Aigner, A. M., Remke, M., & Hansen, F. K. (2018) · MedChemComm · doi:10.1039/c8md00454d · Cited by 18

HDAC Inhibitors

Olzscha, H., Bekheet, M., Sheikh, S., & Thangue, N. B. L. (2016) · Methods in molecular biology · doi:10.1007/978-1-4939-3667-0_19 · Cited by 16

Novel Therapies in Myeloproliferative Neoplasms (MPN): Beyond JAK Inhibitors

Economides, M. P., Verstovšek, S., & Pemmaraju, N. (2019) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-019-00538-4 · Cited by 15

The epigenetic function of androgen receptor in prostate cancer progression

Sawada, T., Kanemoto, Y., Kurokawa, T., & Kato, S. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1083486 · Cited by 16

Rationale for HDAC Inhibitor Therapy in Autoimmunity and Transplantation

Hancock, W. W. (2011) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-21631-2_6 · Cited by 15

Structure-based prediction of HDAC6 substrates validated by enzymatic assay reveals determinants of promiscuity and detects new potential substrates

Varga, J. K., Diffley, K., Leng, K. W., Fierke, C. A., & Schueler‐Furman, O. (2022) · Scientific Reports · doi:10.1038/s41598-022-05681-2 · Cited by 17

Heme-Dependent Activation of Neuronal Nitric Oxide Synthase by Cytosol Is Due to an Hsp70-Dependent, Thioredoxin-Mediated Thiol–Disulfide Interchange in the Heme/Substrate Binding Cleft

Morishima, Y., Lau, M., Peng, H., Miyata, Y., Gestwicki, J. E., Pratt, W. B., & Osawa, Y. (2011) · Biochemistry · doi:10.1021/bi200751t · Cited by 15

Identification and characterisation of a novel heat shock protein 90 inhibitor ONO4140

Eachkoti, R., Reddy, M. R. R., Lieu, Y., Cosenza, S., & Reddy, E. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.04.017 · Cited by 14

Functional cooperativity of p97 and histone deacetylase 6 in mediating DNA repair in mantle cell lymphoma cells

Vekaria, P., Kumar, A., Subramaniam, D., Dunavin, N., Vallurupalli, A., Schoenen, F. J., Ganguly, S., Anant, S., McGuirk, J. P., Jensen, R. A., et al. (2019) · Leukemia · doi:10.1038/s41375-018-0355-y · Cited by 16

Proof of interaction between Leishmania SIR2RP1 deacetylase and chaperone HSP83

Monte-Alegre, A. F., Vergnes, B., Poncet, J., Mathieu-Daudé, F., Cordeiro‐da‐Silva, A., Ouaissi, A., & Séréno, D. (2006) · Parasitology Research · doi:10.1007/s00436-006-0352-3 · Cited by 15

Regulation of ERα Signaling Pathway in Neuronal HN10 Cells: Role of Protein Acetylation and Hsp90

Suuronen, T., Ojala, J. O., Hyttinen, J. M. T., Kaarniranta, K., Thornell, A., Kyrylenko, S., & Salminen, A. (2008) · Neurochemical Research · doi:10.1007/s11064-008-9622-z · Cited by 15

Assays for pharmacodynamic analysis of histone deacetylase inhibitors

Chung, E. J., Lee, M.-J., Lee, S., & Trepel, J. B. (2006) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2.2.213 · Cited by 15

Histone deacetylase inhibitors: a survey of recent patents

Weinmann, H., & Ottow, E. (2005) · Expert Opinion on Therapeutic Patents · doi:10.1517/13543776.15.12.1677 · Cited by 15

Bortezomib and belinostat inhibit renal cancer growth synergistically by causing ubiquitinated protein accumulation and endoplasmic reticulum stress

Asano, T., Sato, A., Isono, M., Okubo, K., Ito, K., & Asano, T. (2015) · Biomedical Reports · doi:10.3892/br.2015.523 · Cited by 14

Developmental Therapeutics in Myeloproliferative Neoplasms

Bose, P., & Verstovšek, S. (2017) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2017.02.014 · Cited by 15

Enhancer of Polycomb and the Tip60 complex repress hematological tumor initiation by negatively regulating JAK/STAT pathway activity

Bailetti, A. A., Negrón-Piñeiro, L. J., Dhruva, V., Harsh, S., Lu, S., Bosula, A., & Bach, E. A. (2019) · Disease Models & Mechanisms · doi:10.1242/dmm.038679 · Cited by 10

Combinations of Histone Deacetylase Inhibitors with Distinct Latency Reversing Agents Variably Affect HIV Reactivation and Susceptibility to NK Cell-Mediated Killing of T Cells That Exit Viral Latency

Covino, D. A., Desimio, M. G., & Doria, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136654 · Cited by 14

HSP90 N‐terminal inhibitors target oncoprotein MORC2 for autophagic degradation and suppress MORC2‐driven breast cancer progression

Yang, F., Sun, R., Hou, Z., Zhang, F.-L., Xiao, Y., Yang, Y., Yang, S., Xie, Y., Liu, Y., Luo, C., et al. (2022) · Clinical and Translational Medicine · doi:10.1002/ctm2.825 · Cited by 13

Ritonavir acts synergistically with panobinostat to enhance histone acetylation and inhibit renal cancer growth

Sato, A., Asano, T., Isono, M., Ito, K., & Asano, T. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.349 · Cited by 14

Acetylome and phosphoproteome modifications in imatinib resistant chronic myeloid leukaemia cells treated with valproic acid

Buchi, F., Pastorelli, R., Ferrari, G., Spinelli, E., Gozzini, A., Sassolini, F., Bosi, A., Tombaccini, D., & Santini, V. (2011) · Leukemia Research · doi:10.1016/j.leukres.2011.01.033 · Cited by 14

HDAC6 deficiency or inhibition blocks FGFR3 accumulation and improves bone growth in a model of achondroplasia

Ota, S., Zhou, Z.-Q., Romero, M. P., Yang, G., & Hurlin, P. J. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw255 · Cited by 13

Revealing protein networks and gene-drug connectivity in cancer from direct information

Jiang, X., Martínez-Ledesma, E., & Morcos, F. (2017) · Scientific Reports · doi:10.1038/s41598-017-04001-3 · Cited by 14

HDAC pharmacological inhibition promotes cell death through the eIF2α kinases PKR and GCN2

Peidis, P., Papadakis, A. I., Rajesh, K., & Koromilas, A. E. (2010) · Aging · doi:10.18632/aging.100216 · Cited by 14

Shifting the paradigm in treating multi-factorial diseases: polypharmacological co-inhibitors of HDAC6

Chan, A. M., & Fletcher, S. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00286k · Cited by 13

Laboratory tumor lysis syndrome complicating LBH589 therapy in a patient with acute myeloid leukaemia

Kalff, A., Shortt, J., Farr, J., McLennan, R., Lui, A., Scott, J. W., & Spencer, A. G. (2007) · Haematologica · doi:10.3324/haematol.11933 · Cited by 13

A duplexed phenotypic screen for the simultaneous detection of inhibitors of the molecular chaperone heat shock protein 90 and modulators of cellular acetylation

Hardcastle, A., Tomlin, P., Norris, C., Richards, J., Cordwell, M., Boxall, K. J., Rowlands, M., Jones, K., Collins, I., McDonald, E., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0496 · Cited by 13

Dual Blockade of Misfolded Alpha-Sarcoglycan Degradation by Bortezomib and Givinostat Combination

Hoch, L., Bourg, N., Degrugillier, F., Bruge, C., Benabidès, M., Pellier, E., Tournois, J., Mahé, G., Maignan, N., Dawe, J., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.856804 · Cited by 12

Selective inhibition of histone deacetylase 6 alters the composition of circulating blood cells in a lethal septic model

Zhao, T., Li, Y., Liu, B., Halaweish, I. F., Mazitschek, R., & Alam, H. B. (2014) · Journal of Surgical Research · doi:10.1016/j.jss.2014.01.056 · Cited by 13

Suberoylanilide hydroxamic acid enhances chemosensitivity to 5-fluorouracil in hepatocellular carcinoma via inhibition of thymidylate synthase

Liao, B., Liang, H., Chen, J., Liu, Q., Zhang, B., & Chen, X. (2015) · Tumor Biology · doi:10.1007/s13277-015-3497-9 · Cited by 12

Investigational histone deacetylase inhibitors for non-Hodgkin lymphomas

Watanabe, T. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.504710 · Cited by 12

Prolactin Drives a Dynamic STAT5A/HDAC6/HMGN2 Cis -Regulatory Landscape Exploitable in ER+ Breast Cancer

Craig, J. M., Turner, T. H., Harrell, J. C., & Clevenger, C. V. (2021) · Endocrinology · doi:10.1210/endocr/bqab036 · Cited by 14

New Insights into the Androgen-Targeted Therapies and Epigenetic Therapies in Prostate Cancer

Godbole, A. M., & Njar, V. C. O. (2011) · Prostate Cancer · doi:10.1155/2011/918707 · Cited by 12

Mechanism for the Differentiation of EoL-1 Cells into Eosinophils by Histone Deacetylase Inhibitors

Kaneko, M., Ishihara, K., Takahashi, A., Hong, J., Hirasawa, N., Zee, O., & Ohuchi, K. (2007) · International Archives of Allergy and Immunology · doi:10.1159/000101401 · Cited by 12

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)

Chandrasekaran, B., Tapadar, S., Wu, B., Saran, U., Tyagi, A., Johnston, A., Gaul, D. A., Oyelere, A. K., & Damodaran, C. (2023) · Cancers · doi:10.3390/cancers15061769 · Cited by 11

Regulation of HDAC6 Catalytic Activity in Cancer: The Role of Post-Translational Modifications and Protein–Protein Interactions

Asaad, L., Pepperrell, B., McErlean, E. M., & Furlong, F. M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031274 · Cited by 11

Recent Advancements in the Development of HDAC/Tubulin Dual-Targeting Inhibitors

Hamzé, A., & Tran, C. (2025) · Pharmaceuticals · doi:10.3390/ph18030341 · Cited by 12

Impact of butyrate on PKM2 and HSP90β expression in human colon tissues of different transformation stages: a comparison of gene and protein data

Jahns, F., Wilhelm, A., Greulich, K. O., Mothes, H. K., Radeva, M. Y., Wölfert, A., & Glei, M. (2011) · Genes & Nutrition · doi:10.1007/s12263-011-0254-6 · Cited by 11

Role of HDAC6 inhibition in sepsis‑induced acute respiratory distress syndrome (Review)

Zhang, Q., Wang, Y., Qu, D., Yu, J., & Yang, J. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9866 · Cited by 11

The Implication of Cancer Progenitor Cells and the Role of Epigenetics in the Development of Novel Therapeutic Strategies for Chronic Myeloid Leukemia

Tortorella, S. M., Hung, A., & Karagiannis, T. C. (2014) · Antioxidants and Redox Signaling · doi:10.1089/ars.2014.6096 · Cited by 11

The Histone Deacetylase Inhibitor BML-210 Influences Gene and Protein Expression in Human Promyelocytic Leukemia NB4 Cells via Epigenetic Reprogramming

Borutinskaite, V. V., & Navakauskienė, R. (2015) · International Journal of Molecular Sciences · doi:10.3390/ijms160818252 · Cited by 11

The regulation and function of the heat shock response

Guisbert, E., & Morimoto, R. I. (2012) · Research and perspectives in Alzheimer's disease · doi:10.1007/978-3-642-27928-7_1 · Cited by 10

Promising molecular targets for pharmacological therapy of neurodegenerative pathologies

Неганова, М. Е., Aleksandrova, Y. R., Nebogatikov, V. O., Klochkov, S. G., & Ustyugov, A. A. (2020) · Acta Naturae · doi:10.32607/actanaturae.10925 · Cited by 11

Histone Deacetylase Inhibitors in Non–Small-Cell Lung Cancer

Witta, S. E. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31826df29c · Cited by 11

A cell-based screen for inhibitors of protein folding and degradation

Boschelli, F., Golas, J. M., Petersen, R., Lau, V., Chen, L., Tkach, D., Zhao, Q., Fruhling, D. S., Liu, H., Nam, C.-E., et al. (2010) · Cell Stress and Chaperones · doi:10.1007/s12192-010-0200-3 · Cited by 11

Mechanism-anchored profiling derived from epigenetic networks predicts outcome in acute lymphoblastic leukemia

Yang, X. H., Huang, Y., Chen, J. L., Xie, J., Sun, X. S., & Lussier, Y. A. (2009) · BMC Bioinformatics · doi:10.1186/1471-2105-10-s9-s6 · Cited by 11

Pyrrole‐Based Hydroxamates and 2‐Aminoanilides: Histone Deacetylase Inhibition and Cellular Activities

Valente, S., Conte, M., Tardugno, M., Massa, S., Nebbioso, A., Altucci, L., & Mai, A. (2009) · ChemMedChem · doi:10.1002/cmdc.200900082 · Cited by 11

Inhibition of histone deacetylase (HDAC) 6 sensitizes human leukemia and breast cancer cells to antagonists of heat shock protein (hsp) 90 and/or bortezomib (BZ)

Bhalla, K. N., Bali, P., Balasis, M. E., Fiskus, W. C., Pranpat, M., Rocha, K., Rao, R., Kumaraswamy, S., & Atadja, P. W. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.24.18_suppl.13039

HDAC6 inhibition enhances 17-AAG–mediated abrogation of hsp90 chaperone function in human leukemia cells

Rao, R., Fiskus, W. C., Yang, Y., Lee, P., Joshi, R., Fernandez, P., Mandawat, A., Atadja, P. W., Bradner, J. E., & Bhalla, K. N. (2008) · Blood · doi:10.1182/blood-2008-03-143644 · Cited by 192

Inhibition of Histone Deacetylase (HDAC) 6 and/or Heat Shock Protein (HSP) 90: A Strategy To Abrogate Multi-Level Protective Responses to Misfolded Proteins Induced by Proteasome Inhibitors in Human Leukemia Cells.

Rao, R., Fiskus, W. C., Herger, B. E., Atadja, P. W., & Bhalla, K. N. (2006) · Blood · doi:10.1182/blood.v108.11.257.257 · Cited by 3

Drugging the HDAC6–HSP90 interplay in malignant cells

Krämer, O. H., Mahboobi, S., & Sellmer, A. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.08.001 · Cited by 133

HSP90 inhibition induces selective destabilization of HDAC6 in a subset of tumor cell typesPreprint

Nováková, Z., Vošahlíková, M., Tuckova, R., Havlínová, B., & Bařinka, C. (2025) · Research Square · doi:10.21203/rs.3.rs-7155742/v1